Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Economic Development topic
No spam. Unsubscribe anytime.
House backs biotechnology resolution and companion bill to encourage industry and preempt local technical regulation
Summary
The House passed HCR 2 and substitute H.B. 27 to signal a pro‑biotech policy: the state will not enact statutes specific to biotechnology beyond federal requirements, will preempt local technical regulation of processes, and will protect trade secrets except where public health or environment is threatened.
The Utah House advanced a pair of measures on biotechnology on Feb. 11, adopting substitute HCR 2 and later passing substitute H.B. 27, the companion statute.
Representative Jones, author of both measures, described them as products of the governor’s task force and urged the House to send a clear message that Utah is a business-friendly place for biotechnology firms. He said the resolution and statute are meant to avoid duplicative state regulation where federal standards are sufficient and to protect proprietary trade secrets while preserving public-health exceptions.
Members asked whether the resolution amounted to an abdication of legislative oversight. Representative Howard asked whether the House was effectively saying it would “never regulate” — Jones responded that the bill preserves authorities to protect health and the environment and that agencies and local governments would still retain land‑use and safety powers. Committee work and drafting involved the Department of Health, Department of Environmental Quality, and the League of Cities and Towns, Jones said.
On the floor substitute HCR 2 passed by a recorded vote of 63–7. Substitute H.B. 27 — which preempts municipal regulation of technical processes while leaving land-use and public-health regulation intact, and adds confidentiality protections for trade secrets — later passed the House on a recorded vote of 60–10 and was forwarded to the Senate.
What this means: The measures are intended to give a clear policy signal to biotech companies considering moving to Utah that the state will favor federal standards for technical biosafety and guard trade-secret information, while retaining explicit exceptions for public-health and environmental protection.
